49 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 49 of 49 clinical reviews.
Evidence-based AndroGel dosing for men aged 30-49 with hypogonadism: starting doses, titration schedules, application sites, monitoring labs, and when to adjust. prepared by the HealthRX.com Editorial Team.
A physician-level review of how AndroGel (testosterone gel 1% and 1.62%) affects bone mineral density in hypogonadal men, covering T-Trials data, DXA monitoring intervals, and evidence-based clinical protocols.
A physician-level review of every clinically significant drug-drug interaction for AndroGel (testosterone gel 1% and 1.62%), with mechanisms, dosing implications, and monitoring protocols backed by FDA labeling and primary literature.
A comparison of compounded testosterone gel versus branded AndroGel, covering pharmacokinetics, cost, safety, regulatory status, and how to choose between them.
Compare AndroGel pricing against generic testosterone gel, injections, patches, pellets, and oral TRT. Includes per-month costs, clinical efficacy data, and insurance considerations.
A guide to AndroGel (testosterone gel 1% and 1.62%) dosing when liver function is compromised, covering pharmacokinetics, FDA labeling, safety monitoring, and clinical decision-making.
A guide to AndroGel (testosterone gel) dosing in chronic kidney disease and renal impairment, covering pharmacokinetics, safety data, monitoring protocols, and how testosterone gel works.
A guide to food, supplement, and nutrient interactions with AndroGel (testosterone gel), including absorption risks, liver enzyme effects, and timing strategies.
Complete clinical guide to AndroGel (testosterone gel 1% and 1.62%) for male hypogonadism. Covers FDA approval, TRT Trials evidence, dosing protocols, side effects, insurance, and answers to common patient questions.
Clinical guide to using AndroGel (testosterone gel 1%) for secondary hypogonadism, including FDA status, dosing protocols, T-Trials evidence, fertility considerations, and insurance coverage.
A deep dive into AndroGel's mechanism of action, current limitations, and the testosterone gel pipeline, including novel transdermal systems, nasal gels, subcutaneous pellets, and oral alternatives backed by PubMed and FDA data.
Evidence-based monitoring protocol for AndroGel (testosterone gel) in men aged 65 and older, covering lab intervals, cardiovascular screening, PSA tracking, hematocrit thresholds, and when to stop therapy.
A guide to AndroGel (testosterone gel 1% and 1.62%) safety in men aged 65 and older, covering cardiovascular risk, falls, polypharmacy, renal considerations, and when deprescribing makes sense.
Evidence-based AndroGel dosing guidance for men aged 65 and older, covering starting doses, titration, monitoring, drug interactions, and safety considerations specific to geriatric patients.
A clinician-level review of how AndroGel (testosterone gel 1% and 1.62%) affects scalp hair, body hair, sebum production, acne, and skin thickness, with primary-literature citations and practical management guidance.
A clinical history of AndroGel (testosterone gel), covering its FDA approval, formulation evolution, landmark trials like the T-Trials, patent battles, and role in modern hypogonadism treatment.
Evidence-based guide to testosterone gel (AndroGel) use in special populations including HIV-associated hypogonadism, organ transplant recipients, opioid-induced and glucocorticoid-induced testosterone deficiency.
AndroGel is a topical testosterone gel, not an injectable. Learn the correct application technique, dosing, absorption science, and how it compares to injectable TRT options.
A clinical deep-dive into AndroGel's manufacturing timeline, FDA supply disruptions, testosterone gel production challenges, and current availability status.
A physician-level explanation of how AndroGel (testosterone gel 1%) works, from transdermal absorption through 5α-reductase conversion, androgen receptor activation, and HPG axis feedback.
Evidence-based guide to handling missed doses of AndroGel (testosterone gel 1% and 1.62%). Covers the pharmacokinetic basis for the FDA-labeled missed-dose instruction, what is and is not established about recovery timing, and when a missed dose becomes a reason to call your prescriber.
A complete guide to monitoring testosterone levels, hematocrit, PSA, and metabolic markers while using AndroGel (testosterone gel) in men aged 30 to 49.
A guide to monitoring AndroGel (testosterone gel) in men aged 50, 64, covering serum testosterone targets, hematocrit, PSA, cardiovascular risk, and polypharmacy considerations with primary-source citations throughout.
A physician-level guide to the lab tests, physical exams, and follow-up intervals required while using AndroGel (testosterone gel), with timelines drawn from AES, Endocrine Society, and FDA guidance.
Evidence-based guide to testosterone gel (AndroGel) overdose management, including signs of accidental excess dosing, secondary transfer risks, FDA safety data, and step-by-step clinical response protocols.
A breakdown of AndroGel's patent history, generic testosterone gel options, mechanism of action, and what the T-Trials show about efficacy. Includes dosing, bioavailability data, and FDA approval dates.
Genetic variants in AR, SRD5A2, UGT2B17, and CYP19A1 alter how men absorb, metabolize, and respond to AndroGel (testosterone gel). Here is what the pharmacogenomic evidence means for TRT dosing.
AndroGel half life: free testosterone clears in 10 to 100 minutes, but skin-reservoir release means levels fall to baseline 48 to 72 hours after stopping.
Complete clinical guide to the AndroGel (testosterone gel 1%/1.62%) pre-surgery hold window: how long to stop before procedures, why polycythemia and thrombotic risk drive the recommendation, and what labs to check before resuming.
AndroGel (testosterone gel) carries an FDA Category X rating in pregnancy and poses secondary transfer risks during lactation. This guide covers teratogenicity data, transfer mechanisms, contraceptive requirements, and safe handling protocols.
A clinical review of real-world evidence for AndroGel (testosterone gel), including registry data from RHYME, T-Trials outcomes, TRAVERSE cardiovascular findings, and claims-database analyses of adherence and safety.
Stopping AndroGel triggers predictable hormonal rebound effects including suppressed LH, FSH, and endogenous testosterone. Learn what the clinical evidence says, how long recovery takes, and what your doctor can prescribe to speed restoration.
A clinical review of AndroGel (testosterone gel) regulatory approvals, prescribing restrictions, and market availability across the United States, European Union, Canada, and United Kingdom.
A guide to AndroGel (testosterone gel 1% and 1.62%) safety for men ages 50 to 64, covering cardiovascular risk, prostate monitoring, polypharmacy, dosing, and what the T-Trials data actually show.
A guide to AndroGel (testosterone gel) safety for men aged 18, 29, covering fertility, bone health, cardiovascular risk, dosing, and monitoring protocols based on current evidence.
A clinical review of every major FDA safety action on AndroGel (testosterone gel), from the 2014 cardiovascular review through the 2023 TRAVERSE trial, with primary-source citations.
AndroGel storage temperatures, expiration dates, heat or freezing exposure, product-specific blood-test timing and practical handling of pumps and packets.
A clinical guide to switching from AndroGel (testosterone gel 1% or 1.62%) to other testosterone formulations, or switching to AndroGel from injections, pellets, or patches. Includes dosing conversions, washout timing, and monitoring benchmarks.
A week-by-week breakdown of what to expect in your first month on AndroGel (testosterone gel 1% / 1.62%), backed by primary clinical trial data and physician-level dosing guidance.
A detailed guide to Aetna (CVS Health) AndroGel coverage, prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial.
Anthem (Elevance Health) covers AndroGel with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and cost-saving strategies.
A complete guide to Blue Cross Blue Shield (Federated) AndroGel coverage, prior authorization criteria, step therapy requirements, formulary tier placement, and how to appeal a denial.
A guide to Humana coverage of AndroGel (testosterone gel 1% and 1.62%), including formulary tiers, prior authorization criteria, step therapy requirements, and how to appeal a denial.
A detailed guide to Kaiser Permanente's AndroGel coverage policy, formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial, with clinical evidence and cost data.
Medicare Advantage plans typically cover AndroGel (testosterone 1.62% gel) for diagnosed male hypogonadism under Part D, but prior authorization and step therapy are standard. Learn formulary tiers, PA criteria, appeal steps, and cost-saving alternatives.
State Medicaid coverage for AndroGel (testosterone gel 1%) varies widely. Learn which states cover it, prior authorization requirements, step therapy rules, formulary tiers, and how to appeal a denial.
A complete guide to TRICARE coverage for AndroGel (testosterone gel 1%/1.62%), including formulary tier, prior authorization criteria, step therapy requirements, and how to appeal a denial.
UnitedHealthcare typically covers AndroGel (testosterone gel 1%) as a Tier 3 brand drug with prior authorization for diagnosed male hypogonadism. Learn about formulary status, PA criteria, step therapy, appeals, and cost-saving strategies.
Evidence-based protocol for safely discontinuing AndroGel (testosterone gel), including taper strategies, HPG axis recovery timelines, lab monitoring, and symptom management.